Correspondence 0001193125-24-180408 from KalVista Pharmaceuticals, Inc. (KALV) (CIK 0001348911) (KALV)
KalVista Pharmaceuticals, Inc. (KALV) (CIK 0001348911)
Date: July 17, 2024 · CIK: 0001348911 · Accession: 0001193125-24-180408
AI Filing Summary & Sentiment
File numbers found in text: 333-280759
Letter
KALVISTA PHARMACEUTICALS, INC.
55 Cambridge Parkway
Suite 901E
Cambridge, Massachusetts 02142
July 17, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Tamika Sheppard
Re: KalVista Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed July 11, 2024
File No. 333-280759
Requested Date: July 19, 2024
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
KalVista Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Julia Forbess or Robert A. Freedman, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Forbess at (415) 875-2420 or, in her absence, to Mr. Freedman at (206) 389-4524.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Sincerely,
KALVISTA PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP KALVISTA PHARMACEUTICALS, INC. 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 July 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Tamika Sheppard Re: KalVista Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 11, 2024 File No. 333-280759 Requested Date: July 19, 2024 Requested Time: 4:30 PM Eastern Time Ladies and Gentlemen: KalVista Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Julia Forbess or Robert A. Freedman, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Forbess at (415) 875-2420 or, in her absence, to Mr. Freedman at (206) 389-4524. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] Sincerely, KALVISTA PHARMACEUTICALS, INC. By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer cc: Robert A. Freedman, Esq. Julia Forbess, Esq. Fenwick & West LLP